Bright Minds Biosciences(DRUG.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Bright Minds Biosciences
DRUG.US
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc.
1.880 T
DRUG.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) has received a consensus rating of "Moderate Buy" from eight research firms. One analyst rated it as a hold, while seven recommended buying. The average 1-year price target is $115.40. Recent reports include HC Wainwright's buy rating with a $115 target, Zacks downgrading to hold, and Cantor Fitzgerald's overweight rating. Institutional investors hold 40.52% of the stock, which has seen significant trading activity. The stock opened at $86.75, with a 12-month range of $23.17 to $123.75.

    Market Beat·
    US
    DRUG
    -2.12%
    Market Beat·
    US
    DRUG
    -2.12%

    Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen

    Wall Street Zen downgraded Bright Minds Biosciences (NASDAQ:DRUG) from a "hold" to a "sell" rating. Despite this, several analysts maintain positive outlooks, with Cantor Fitzgerald reaffirming an "overweight" rating and BTIG Research raising the price target to $147. The stock has a consensus rating of "Moderate Buy" with an average target price of $115.40. Bright Minds focuses on developing therapeutics for mental health and neurodegenerative disorders, with its lead candidate in clinical development for mood and anxiety disorders.

    Market Beat·
    US
    DRUG
    -2.12%
    Market Beat·
    US
    DRUG
    -2.12%

    Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | DRUG Stock News

    Bright Minds Biosciences Inc. has successfully closed a public offering of 1,945,000 common shares at US$90.00 each, raising gross proceeds of US$175 million. The funds will support clinical trials for drug candidates targeting neurological disorders. The company has granted underwriters a 30-day option to purchase additional shares. The offering was conducted under a shelf registration statement approved by the SEC. Bright Minds focuses on developing innovative treatments for neurological and psychiatric conditions.

    StockTitan·
    US
    DRUG
    -2.12%
    StockTitan·
    US
    DRUG
    -2.12%

    Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock | DRUG Stock News

    Bright Minds Biosciences Inc. has announced the pricing of its public offering of 1,945,000 common shares at $90.00 each, aiming for gross proceeds of $175 million. The offering includes a 30-day option for underwriters to purchase an additional 291,750 shares. Proceeds will fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, among other uses. The offering is expected to close on January 9, 2026. The company has also terminated its previous at-the-market equity offering program.

    StockTitan·
    US
    DRUG
    -2.12%
    StockTitan·
    US
    DRUG
    -2.12%

    BUZZ-Bright Minds Biosciences falls after $100 mln equity offering launched

    Bright Minds Biosciences' shares fell 11.8% to $82.25 following a $100 million equity offering announcement. The Canadian biotech firm had previously seen a surge of up to 55% after positive Phase 2 trial results for its epilepsy drug, BMB-101. TD Cowen maintains a 'buy' rating, noting the trial data exceeded expectations. The company plans to use the proceeds for future clinical trials. Analysts remain optimistic, with a median price target of $142.

    Reuters·
    US
    DRUG
    -2.12%
    Reuters·
    US
    DRUG
    -2.12%
    Posts
    View More

    Recursion Pharmaceuticals (RXRX) $Recursion Pharmaceuticals(RXRX.US) In-depth Research Report: From Phenotypic Screening to Vertical Integration—Revaluation After Exscientia Acquisition and the New Pa......

    • 0
    © 2026 Longbridge｜Disclaimer